Theravance Biopharma (TBPH) Other financing activities (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Other financing activities of $241000.0 for Q1 2026, down 50.61% quarter-over-quarter from $488000.0 in Q4 2025.
Theravance Biopharma (TBPH) Other financing activities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Other financing activities for 14 consecutive years, with $241000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $241000.0; the TTM figure through Mar 2026 stood at $862000.0 (changed N/A YoY), while the FY2025 annual figure was $766000.0, up 50.79% from the prior year.
- Other financing activities eased to $241000.0 in Q1 2026 per TBPH's latest filing, from $488000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $21.0 million in Q4 2022 and bottomed at -$20.7 million in Q3 2022.
- Historically, Other financing activities has averaged $192714.3 across 5 years, with a median of $173000.0 in 2023.
- On a YoY basis, Other financing activities climbed as much as 3375.33% in 2022 and fell as far as 823.7% in 2022.
- Theravance Biopharma's Other financing activities stood at $21.0 million in 2022, then sank by 99.18% to $173000.0 in 2023, then retreated by 23.12% to $133000.0 in 2024, then soared by 266.92% to $488000.0 in 2025, then tumbled by 50.61% to $241000.0 in 2026.
- Business Quant data shows TBPH's Other financing activities at $241000.0 in Q1 2026, $488000.0 in Q4 2025, and $133000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | 241,000.00 |
| Mar 31, 2026 | 241,000.00 |
| Dec 31, 2025 | 488,000.00 |
| Dec 31, 2025 | 488,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Dec 31, 2023 | 173,000.00 |
| Dec 31, 2023 | 173,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Dec 31, 2022 | 20.99 Mn |
| Dec 31, 2022 | 20.99 Mn |
| Sep 30, 2022 | -20.68 Mn |
| Sep 30, 2022 | -20.68 Mn |
| Dec 31, 2021 | 604,000.00 |
| Dec 31, 2021 | 604,000.00 |
| Sep 30, 2021 | 2.86 Mn |
| Sep 30, 2021 | 2.86 Mn |